Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration

Haichao Tang1,2 | Wensi Liu1,2 | Zhaoxu Xu1,2 | Jianhang Zhao1,2 | Weitao Wang1,2 | Zhaojin Yu1,2 | Minjie Wei1,2

1Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
2Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumours, Ministry of Education, China Medical University, Shenyang, China

Correspondence
Zhaojin Yu, Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, China. Email: yuzhaojin19830813@163.com
Minjie Wei, Department of Pharmacology, School of Pharmacy, China Medical University, No.77, Puhe Road, Shenyang North New Area, Shenyang, Liaoning, 110122, China. Email: weiminjiecmu@163.com

Abstract
Glioblastoma (GBM) is the most common malignant intracranial tumour with intrinsic infiltrative characteristics, which could lead to most patients eventually relapse. The prognosis of recurrent GBM patients remains unsatisfactory. Cancer cell infiltration and their interaction with the tumour microenvironment (TME) could promote tumour recurrence and treatment resistance. In our study, we aimed to identify potential tumour target correlated with rGBM microenvironment based on the gene expression profiles and clinical information of rGBM patients from The Cancer Genome Atlas (TCGA) database. LRRC15 gene with prognostic value was screened by univariate and multivariate analysis, and the correlation between macrophages and LRRC15 was identified as well. Furthermore, the prognosis correlation and immune characteristics of LRRC15 were validated using the Chinese Glioma Genome Atlas (CGGA) database and our clinical tissues by immunochemistry assay. Additionally, we utilized the transwell assay and carboxy fluorescein succinimidyl ester (CFSE) tracking to further confirm the effects of LRRC15 on attracting microglia/macrophages and tumour cell proliferation in the TME. Gene profiles-based rGBM microenvironment identified that LRRC15 could act in collusion with microglia/macrophages in the rGBM microenvironment to promote the poor prognosis, especially in mesenchymal subtype, indicating the strategies of targeting LRRC15 to improve macrophages-based immunosuppressive effects could be promising for rGBM treatments.

KEYWORDS
immunology, LRRC15, macrophages, recurrent glioblastoma, tumour microenvironment
INTRODUCTION

Glioblastoma (GBM) is the most frequent malignant intracranial tumour, accounting for 47.1% of all malignant central nervous system tumours,1 and remains poor survival. The estimated median overall survival in primary GBM is 14.6 mo, and the two-year survival rate is 26.5% after surgery and radiotherapy combined temozolomide.2 Furthermore, GBM nearly irresistible relapse because of intrinsic infiltrative characteristics. The median overall survival is about 24-44 wk of recurrent GBM (rGBM).3 Currently, most studies mainly focussed on the primary and untreated tumours, while the biology and treatment design of rGBM remains challenging. Additionally, the current treatments could not effectively eradicate infiltrative tumour cells to reverse recurrence of GBM and could induce tumour cells to produce therapy-resistance.4 Therefore, novel treatment strategies for GBM, especially for rGBM, are urgently needed.

Previous studies indicated that cancer cell proliferation and their interaction with the tumour microenvironment (TME) contributed to tumour recurrence and treatment resistance.5 GBM microenvironment is full of multiple immunosuppressive mechanisms, including the secretion of immune suppressive factors, the up-regulation of suppressive factors on the cell surface, the abatement of T cells and NK cells, and the expansion of immune suppressive cells.6 The current immunotherapeutic approaches mainly focus on the checkpoint blockades with CD8+ T cells activation effects, such as Checkmate 143 (NCT02017717), whereas which did not get decent results.7,8 Therefore, concentrating on disrupting the immunosuppressive barrier directly could be a promising window for GBM treatments. Glioblastoma-associated macrophages (GAMs) are the most dominant immune suppressive cells in the GBM microenvironment,9 which are derived from brain-resident microglia/monocytes and peripheral monocytes/macrophages that tend to develop into the M2-like phenotype in the GBM microenvironment.10 Meng et al suggested M2-like macrophages could contribute to radiotherapy resistance,11 indicating eradiating macrophages effects immunotherapy could play a radiosensitizing role. Similarly, M2-like macrophages could generate reactive oxygen and nitrogen intermediates to limit the effectiveness of chemotherapy and targeted molecular therapies.12,13 In particular, the mesenchymal subtype with more degree malignancy in rGBM was associated with limited clinical response and radioresistance,14 largely because of the infiltration of GAMs as well.15,16 Therefore, impeding GAMs recruitment into the microenvironment could be a promising treatment strategy for improving the prognosis of rGBM.

The type I transmembrane protein 15-leucine-rich repeat containing membrane protein (LRRC15) is a member of the LRR superfamily that is thought to be involved in protein-protein and protein-matrix interactions, and signal transduction for various cellular processes.17-19 Previous studies demonstrated LRRC15 was highly expressed on cancer cells of mesenchymal origin with low normal tissue expression.20 However, the role of LRRC15 in rGBM has not been delineated.

In this study, we explored the microenvironment-associated genetic landscapes in rGBM based on Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression (ESTIMATE) data through The Cancer Genome Atlas (TCGA) database. LRRC15 and its role in GAMs infiltration were identified. Besides, our study further integrated Chinese Glioma Genome Atlas (CGGA) data sets21,22 and experimental methods to comprehensively confirm the prognostic value of LRRC15 and relationship between GAMs infiltration and LRRC15 expression.

METHODS AND MATERIALS

2.1 Gene expression database

The Level 3 gene expression profiles of rGBM patients were obtained on 30 March, 2019 from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/). Clinical data, including subtypes and survival time, were also obtained from TCGA data portal. All gene expression were used as RNA-seq by expectation-maximization (RSEM). Level 3 gene expression profiles and clinical data of rGBM patients were downloaded on 6 May, 2020 from the Chinese Glioma Genome Atlas (CGGA) data set (mRNAseq_693, mRNAseq_325, Illumina HiSeq and mRNAseq_325,23,24 Illumina HiSeq 2,000 or 2,500) as validation (http://www.cgga.org.cn/). The mRNAseq_693 data set contained 109 rGBM samples. The mRNAseq_325 data set contained 24 rGBM samples.

2.2 Analysis of genes

Immune scores and stromal scores were calculated based on the ESTIMATE algorithm.25 All RNA expression data were divided into high/low immune score groups and high/low stromal score groups. Fold change >1.5 and adj. P < 0.05 were set as the cut-offs to mine differential genes. Also, differential analysis of recurrent and primary GBM was performed with package edgeR. False-positive discovery (FDR) < 0.05 and |log2 (fold change)| >1 were set as the cut-offs to obtain differentially expressed genes (DEGs). The heatmaps and volcano maps were generated with R software.

Kaplan-Meier plots were used to illustrate the correlation between patients’ overall survival and differential gene expression levels. The correlation was tested by log-rank test. Univariate and multivariate analysis of key genes were further conducted using Cox regression.

Gene Ontology (GO) analysis was performed to identify the potential function of intersection genes using the clusterProfiler package in R software, and we were only interested in the significance level (P < 0.05 and enrichment >2).

Gene Set Enrichment Analysis (GSEA) between LRRC15 high expression and low expression was performed using GSEA 3.0. (https://www.gsea-msigdb.org/gsea/index.jsp). The macrophages metagenes of GSEA were referenced based on the published study.26 LRRC15 expression in multiple cells was analysed using Human Protein Atlas (https://www.proteinatlas.org).
2.3 | Immunohistochemistry assay

The 42 cases of human rGBM tissue samples as paraffin tissues microar-rays and corresponding clinical data were obtained from the Fourth hospital of China medical university between January 2017 and March 2019. LRRC15 was evaluated using primary antibody (Anti-LRRC15 antibody, 1:50, NPB1-93556, Novus), and CD206 was evaluated using primary antibody (Anti-Mannose antibody, 1:100, ab64923, abcam). The secondary antibody (Goat anti-rabbit IgG, 1:50, ZDR-5306; Zhongshan Gold Bridge Biotechnology, China) was used and the signal was detected using the DAB Kit (ZLI-9018; Zhongshan Gold Bridge Biotechnology, China). The LRRC15 and CD206 expression were evaluated by two experienced researchers. The immunohistochemical staining intensity was scored on a scale of 0-3 (0, no stain; 1, weak stain, 2, medium stain; 3, strong stain). The percentage of positive staining cells (0 to 100%) multiplied the score of immunohistochemical staining intensity (0-3) equals the IHC scoring.

2.4 | Cell culture and generation of THP-1-derived M2-like macrophages

U-87 MG cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, 12 800 017) containing 10% FBS. Human monocyte cell lines (THP-1) were cultured in RPMI-1640 medium (Gibco, 31 800 022) with 10% FBS. All cells were cultured at 37°C with 5% CO₂. THP-1 cells were purchased from the Cell Resource Center of the Shanghai Institute (Shanghai, China). U-87 MG cell lines were purchased from Beina Bio (Beijing, China). 1×10⁶ THP-1 cells were treated with 100 ng/ml Phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich) for 48h, and then added 25 ng/ml IL-4 (Peprotech) for 48h to generate M2-like macrophages for further research. The CD206 expression was evaluated with a FITC anti-human CD206 (Biolegend, 321 103) by flowcytometry. The CD206 mRNA expression and PD-L1 mRNA expression were detected using real-time PCR.

2.5 | siRNA and real-time PCR

The three human siRNA sequences were provided by Ribobio (Guangzhou, China). Seeding cells with 2 ml medium contain 1 μg siRNA and 2 μl Lipofectamine™ 2000 (11,668,019; Thermo Fisher Scientific, USA) for 6 h at 37°C, then the medium was replaced with complete medium. The cells were collected after 48 h. Total RNA was extracted from U-87 MG cell lines using TRIzol reagent (R1100, Solarbio, China) according to the manufacturer’s instructions. After the gene-silencing experiment, real-time PCR was used to verify that LRRC15 gene product was successfully knocked down. The synthesis of cDNA was performed with PrimeScriptTM RT Master Mix Kit (RR036A; TAKARA, Tokyo, Japan). Real-time PCR analysis was performed by TB Green® Premix Ex TaqTM II Kit (RR820A; TAKARA, Tokyo, Japan) in the Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems, Foster City, USA). The relative gene expression was calculated using the 2-ΔΔCT method. The primer sequences were used as follows: LRRC15 (forward, 5′-GCCCTGTATGTACTGCTTTAACTC-3′; reverse, 5′-GGATAATGCCATTCCAATGTGTT-3′); CD206 (forward, 5′-CTCTAAGCTAATCTCCGTT-3′; reverse, 5′-ATGATCTGCGACTCCGAAC-3′); PD-L1 (forward, 5′-TGAGGTTGCGTTTGACGTTT-3′; reverse, 5′-TGACGGAGGCTACATTGGTTT-3′). The expression level of LRRC15, CD206, and PD-L1 was standardized to GAPDH (Ribobio, China).

2.6 | Transwell migration assay

The cell line U-87 MG cells with or without LRRC15 knockdown were seeded on Day 0, and the culture supernatants were harvested on Day 8. Transwell inserts (Pore size 8.0 μm, Corning, 3422) were placed onto a 24-well plate. A total of 500 μl of conditioned supernatant were applied to the bottom of well.
This was followed by the addition of 200 µl of THP1-derived macrophages on the top of the inserts. After 48 h incubation at 37 ºC with 5% CO2, the insert membranes were stained with crystal violet, were dried and photographed underneath the membranes using a Nikon Eclipse TS100 Microscope (Nikon, Japan).
FIGURE 2 Prognostic immune-associated genes of recurrent glioblastoma from TCGA database. (A) Heatmap of differential gene profiles (Top 100) based on immune scores and stroma scores. *P* < 0.05, fold change > 1. (B) Venn diagrams showing the number of up-regulated or down-regulated interaction genes in immune score groups and stroma score groups. (C) GO analysis of interaction genes. GO, Gene Ontology; BP, Biological process. (D) Volcanic plot visualizing the DEGs between primary and recurrent glioblastoma. DEGs, differentially expressed genes. *P* < 0.05, fold change > 1. (E) Venn diagrams showing the prognostic interaction genes between up-regulated immune-associated genes and DEGs. (F) Kaplan-Meier survival curves for the association of the five genes expression with OS in rGBM patients. *P* < 0.05 in log-rank tests. (G) Univariate and multivariate Cox regression analysis explored the correlation between the gender, age, LRRC15, MLPH, RARRES1, TWIST2, C5orf46, TMT, HT, IDH status, and MGMT protomer status, and the OS. TMT, targeted molecular therapy; HT, hormone therapy; MGMT, methylation status of the 6-methylguanine-DNA methyl-transferase (MGMT); OS, overall survival.

### TABLE 1 The genes with prognostic value

| gene    | median survival time (low/high) | *P*-value |
|---------|---------------------------------|-----------|
| CTHRC1  | 543/405                         | 0.04640013|
| ENTHD1  | 480/399                         | 0.03209777|
| LOXL2   | 543/395                         | 0.04712455|
| THBD    | 485/399                         | 0.03610763|
| RARRES1 | 535/405                         | 0.02545571|
| MMP1    | 485/395                         | 0.03576519|
| SOCS3   | 489/399                         | 0.01850587|
| LSP1    | 505/385                         | 0.02705352|
| FN1     | 505/375                         | 0.01360658|
| COL6A3  | 489/385                         | 0.04952642|
| FOSL1   | 543/394                         | 0.00592895|
| MMP19   | 505/399                         | 0.04172311|
| NEU4    | 399/535                         | 0.01619315|
| ELF5    | 489/427                         | 0.03177262|
| STC1    | 532/360                         | 0.00060505|
| BDKRB2  | 548/394                         | 0.02712349|
| C5orf46 | 489/399                         | 0.01214094|
| KRT80   | 548/394                         | 0.01665271|
| TMEM26  | 485/399                         | 0.03432677|
| SLC17A9 | 532/385                         | 0.03520527|
| ADAMTS14| 532/399                         | 0.00367251|
| CXCL5   | 505/394                         | 0.00539419|
| ANKRD1  | 598/405                         | 0.01065263|
| BAIAP2L1| 535/399                         | 0.00983912|
| COL5A1  | 489/399                         | 0.04073292|
| MXRA5   | 532/399                         | 0.00927983|
| VDR     | 489/385                         | 0.02797673|
| LRRC15  | 505/362                         | 0.00782462|
| TFF1    | 489/405                         | 0.03295255|
| THBS1   | 489/399                         | 0.01906768|
| ADAM8   | 485/442                         | 0.02581667|
| TPSAB1  | 489/375                         | 0.04994894|
| INHBA   | 543/399                         | 0.03764112|
| ST8S1A5 | 532/448                         | 0.03742567|
| TWIST2  | 489/405                         | 0.03159857|

(Continues)

### TABLE 1 (Continued)

| gene    | median survival time (low/high) | *P*-value |
|---------|---------------------------------|-----------|
| AQP9    | 485/394                         | 0.03640032|
| FAM81B  | 480/448                         | 0.03524028|
| RFX8    | 532/399                         | 0.00599177|
| FAM20A  | 505/399                         | 0.02481316|
| TMEM200B| 505/399                         | 0.02056244|
| IL11    | 505/394                         | 0.02994168|
| AKR1B15 | 406/543                         | 0.02706454|
| PLBD1   | 489/394                         | 0.04990027|
| SCG3    | 399/535                         | 0.00805953|
| FOLR2   | 442/505                         | 0.02990027|
| PCOLCE  | 532/394                         | 0.02753339|
| CCR7    | 532/385                         | 0.02041857|
| ARSI    | 603/406                         | 0.02692185|
| COL1A1  | 489/394                         | 0.03218838|
| ANKEF1  | 548/385                         | 0.0013287|
| MLPH    | 532/394                         | 0.00556484|
| SLAMF8  | 505/399                         | 0.04154503|
| ORM1    | 489/395                         | 0.02140396|
| CDCP1   | 505/375                         | 0.03704625|
| HMGA2   | 548/394                         | 0.00994343|
| TGFBI   | 485/399                         | 0.03234585|
| IL7R    | 489/442                         | 0.03066649|
| RETN    | 505/399                         | 0.00718056|
| HESS    | 399/489                         | 0.04545999|
| COL6A2  | 548/399                         | 0.01713164|
| MMP11   | 548/399                         | 0.00955575|

2.7 Cell proliferation by carboxy fluorescein succinimydyl ester (CFSE) tracking

The THP-1 cells were seeded in transwell inserts (Pore size 0.4 μm, Corning, 3412) and were differentiated into M2-like macrophages according to the above-described method. The U-87 MG cells with/without LRRC15 knockdown were labelled with carboxy fluorescein succinimydyl ester (CFSE, C375, DOJINDO) and were seeded into 6 well plates. Setting up the co-culture system by combining the
THP-1-derived M2-like macrophages and CFSE-labelled U-87 MG cells with/without LRRC15 knockdown on the same plate. On d 4, U-87 MG cells were obtained and the level of cell proliferation was tested by flow cytometry.

### 2.8 Statistical analysis

All data were expressed as mean ± SD (standard deviation). The Kaplan-Meier survival curves were tested by the log-rank test.
RESULTS

3.1 | Mining microenvironment-associated genes in rGBM microenvironment

We set out to mine genetic profiles that correlate with tumour microenvironment based on immune scores and stromal scores in rGBM (Figure 1). We performed RNA-seq data of 169 recurrent GBM samples culled from TCGA. There were 844 up-regulated genes and 180 down-regulated genes in higher immune scores groups by comparing high with low scores groups (|log2 (fold change)| >1, \( P < 0.05 \)). Similarly, 880 up-regulated genes and 221 down-regulated genes were obtained in higher stromal scores groups (|log2 (fold change)| >1, \( P < 0.05 \)). Besides, the intersection genes included 710 up-regulated and 120 down-regulated in higher scores groups (Figure 2A, B). It is worth mentioning that these intersection genes were more closely correlated with tumour purity and played decisive roles in the TME. Furthermore, we identified the potential functional annotation of intersection genes based on Gene Ontology (GO) terms (false discovery rate, or FDR < 0.05, -log FDR >1.301). The results demonstrated that the top terms were 0042119-neutrophil activation, 0031012-extracellular matrix and 0048018-receptor ligand activity (Figure 2C, Figure S1A), which suggested enrichment focussed on microenvironment-associated pathways. To further identify the prognostic relevance of these intersection genes in rGBM patients, Kaplan-Meier survival curves were generated to assess the clinical outcomes of the corresponding genes. The patient overall survival (OS) was assessed based on these genes’ expression, and we identified 61 genes potentially correlated with prognosis among 830 intersection genes using a log-rank test (\( P < 0.05 \), Table 1). To reveal biomarkers can express differentially in the rGBM, we analysed DEGs between recurrent and primary GBM using TCGA RNA-seq datasets, in which 109 up-regulated genes and 209 down-regulated genes were identified (|log2 (fold change)| >1, \( P < 0.05 \), Figure 2D). After that, we integrated these up-regulated DEGs and the above-identified prognosis-associated markers to identify distinctive tumour-specific immune-associated biomarkers further. We identified five up-regulated genes (LRRC15, C5orf46, MLPH, RARRES1 and TWIST2) in rGBM (Figure 2E, F). Notably, we further estimated the prognostic value of the five genes in rGBM patients concerning pharmacological therapy, including hormone therapy and targeted molecular therapy, showing high expression of LRRC15 and RARRES1 contributed to poor prognosis in patients without hormone, C5orf46, RARRES1, TWIST2 promoted poor prognosis in patients without targeted molecular therapy (Figure S1B-E). Furthermore, we performed cox regression analysis to find key genes that could be used as independent risk factors for rGBM prognostic prediction. The univariate Cox regression analysis was used by integrating the mRNA expression profiles and clinical information of the five genes. LRRC15, TWIST2, IDH status and MGMT status were proved to be important predictors for patients with rGBM (\( P < 0.05 \)). A multivariate Cox regression analysis further indicated that LRRC15 expression and MGMT status (\( P < 0.05 \)) were independent risk factors for rGBM prognostic prediction. Therefore, we selected LRRC15 with significant differences in univariate and multivariate cox analysis for further analysis (Figure 2G). The univariate and multivariate Cox regression analysis demonstrated that LRRC15 can be used as an independent risk factor for rGBM prognostic prediction (Figure 2G). These results indicated that LRRC15 might be a potential rGBM target for the development of novel therapeutic strategies.

3.2 | Investigation of potential correlation of LRRC15 gene with infiltration of GAMs in rGBM

We aimed to elucidate whether the expression of LRRC15 might involve in infiltration of GAMs in rGBM. For this purpose, we analysed the potential correlation between macrophages and LRRC15 expression in rGBM. The results demonstrated that LRRC15 expression was indeed correlated with the macrophage gene set (\( \text{P} < 0.001 \)) (Figure 3A). We further explored the relationship between LRRC15 expression and microglia/macrophages markers levels using TCGA database RNA-seq data. We found the significant association between high LRRC15 expression and the high level of integrin subunit alpha M (ITGAM, also known as CD11b), allograft inflammatory factor 1 (AIF1, also known as IBA1) and CD68. In particular, LRRC15 expression was also significantly positively correlated with transcriptional levels of M2-like macrophages markers CD206, CD163 and CD204 but was not positively related to M1-like macrophages markers NOS2 and STAT1 (Figure 3B, Figure S2A, B).
Notably, we quantified the tumour purity of rGBM molecular subtypes using ESTIMATE method. The results showed the mesenchymal subtype had the highest immune and stromal scores (Figure 3C). To define the incidence of microglia/macrophages in distinct rGBM subtypes, we analysed the above-described markers using TCGA database. The results showed markedly higher expression of ITGAM, AIF1, CD206, CD163 and CD204, but not NOS2 and STAT1, in mesenchymal compared with non-mesenchymal subtypes (Figure 3D, E). Next, to get insight into LRRC15 expression in subtypes, we interrogated the expression of LRRC15 in the different

**FIGURE 4** Validation of immune association of LRRC15 in the CGGA data set. (A) Heatmap of differential gene profiles (Top 50) based on immune scores and stroma scores. \( P < 0.05, \text{fold change} > 1, \) including LRRC15. (B) Venn diagrams showing the number of up-regulated or down-regulated interaction genes in immune score groups and stroma score groups. (C) GO analysis of interaction genes. GO, Gene Ontology. BP, Biological process (D) Kaplan-Meier survival curves for the association of LRRC15 expression with overall survival (OS) in rGBM patients. \( P < 0.05 \) in log-rank tests. (E-F) Validation of correlation of LRRC15 and respective markers of microglia/macrophages from CGGA RNA-seq data.
subtypes using TCGA database. Interestingly, the results demonstrated LRRC15 was remarkably high expressed in the mesenchymal subtype (Figure 3F). These data demonstrated that mesenchymal subtypes are better candidates for targeting LRRC15 therapies against GAMs.

3.3 Validation in CGGA database

To validate the immune association and prognostic value of LRRC15, we downloaded mRNAseq_693 from CGGA database.21,22 We chose 109 rGBM cases to quantify TME using the ESTIMATE method. The results demonstrated 1087 up-regulated genes and 945 down-regulated genes in the intersection genes between higher immune score groups and higher stroma score groups (Figure 4A, B). Similarly, we also identified that the intersection genes could enrich in the microenvironment-associated pathways based on Gene Ontology (GO) terms (false discovery rate, or FDR < 0.05, -log FDR > 1.301) (Figure 4C). Fortunately, we found LRRC15 existed in up-regulated intersection genes (Table S1). Furthermore, we verified the correlation of LRRC15 expression with prognostic value in rGBM (Figure 4D). Meanwhile, we confirmed the correlation between LRRC15 expression and macrophages transcriptional levels in the rGBM cases (Figure 4E, F). Besides, the gene profiles from Chinese Glioma Genome Atlas (CGGA) data portal (mRNAseq_325) were collected. The immune association of LRRC15 in rGBM was further validated based on ESTIMATE algorithm. We found 599 up-regulated genes and 122 down-regulated genes in the intersection genes between higher immune score groups and higher stroma score groups (Figure S2C, D). Meanwhile, the intersection genes could enrich in the immune-associated pathways based on Gene Ontology (GO) terms (false discovery rate, or FDR < 0.05, -log FDR > 1.301) (Figure S2E). Similarly, LRRC15 also existed in up-regulated interaction genes (Table S2). Furthermore, LRRC15 expression is enriched in macrophage gene set in rGBM (Figure S2F). These results strengthened the characteristics of LRRC15 correlated with poor prognosis and GAMs infiltration in rGBM.

3.4 Confirmation of LRRC15 expression promoting macrophages infiltration and tumour poor prognosis

In order to further confirm the distinct characteristics of LRRC15 in rGBM, we performed immunohistochemistry assay and Kaplan-Meier survival analysis in clinical samples of rGBM after validation with TCGA database and CGGA data sets. The IHC assay results showed LRRC15 expression was positively correlated with CD206 expression (Figure 5A). Meanwhile, the Kaplan-Meier survival analysis suggested LRRC15 high expression promoted poor prognosis of rGBM patients (Figure 5B). Furthermore, tumour cells have been shown to recruit macrophages.27 We used the Human Protein Atlas (https://www.proteinatlas.org) to analyse the LRRC15 mRNA level in multiple cell lines, and LRRC15 expression showed enhancement in U-87 MG cells (Figure 5C), which made U-87 MG cell line priority. Based on the above-described bioinformatic analysis of the significant correlation between LRRC15 and M2-like macrophages, we sought to confirm the direct connection exists between LRRC15 and M2-like macrophages. The THP-1-derived M2-like macrophages were identified using flowcytometry and real-time PCR (Figure S3). Furthermore, we performed the transwell assay using supernatants derived from GBM cell line U-87 MG with/without LRRC15 knockdown co-cultured with THP-1-derived M2-like macrophages (Figure 5D). The results showed that the supernatants from LRRC15 knockdown U-87 MG cells recruited less M2-like macrophages as compared with the NC group (Figure 5E). Furthermore, to prove the correlation of LRRC15 and the poor prognosis of rGBM, we simulated the TME in a co-culture system to perform the CFSE assay (Figure 5F). The results showed LRRC15 knockdown could inhibit the proliferation of U-87 MG cells compared with the NC group in the presence of M2-like macrophages (Figure 5G). These results from the in vitro experiments suggest that LRRC15 is responsible, at least in part, for the attraction of GAM and proliferation of tumour cells.
LRRRC15 promotes the recruitment of GAMs and proliferation of tumour cells. (A) Representative micrographs of LRRRC15 expression and CD206 expression as well as their expression correlation analysis in human rGBM tissues by immunohistochemistry assay. (B) Kaplan-Meier curve showed the association between LRRRC15 expression and OS in 24 rGBM patients with survival information based on the relative LRRRC15 IHC score divided by the optimal cut-point off. ROC curve analysis of LRRRC15 IHC score was shown based on OS status. (C) LRRRC15 expression in multiple cells from Human Protein Atlas. (D) Schematic diagram of experimental design of tumour LRRRC15 expression influencing M2-like macrophage migration. Supernatants of tumour cell culture were collected on Day 8 after the tumours were seeded and used for the M2-like macrophages migration assay. (E) Migration analysis of M2-like macrophages in the presence of LRRRC15 or LRRRC15 knockdown tumour supernatants by transwell assay. Images were taken 48 h after the M2-like macrophages were exposed to the tumour supernatants. The images represent 1 of 3 individual experiments using THP-1-derived macrophages. (F) Schematic diagram of experimental design of tumour LRRRC15 expression influencing tumour proliferation in the presence of M2-like macrophages. THP-1 cells were induced into M2-like macrophages and co-cultured with U-87 MG cells with/without LRRRC15 knockdown for CFSE assay. (G) CFSE assay was used to examine the tumour cells proliferation with/without LRRRC15 knockdown.

chemotherapy tolerance, angiogenesis and metastasis of GBM.\textsuperscript{4,41} indicating GAMs are important parameters to consider in developing immunotherapeutic strategies of GBM. Gene Ontology (GO) analysis of the study also validated that these TME-associated genes are involved in leucocyte migration in rGBM. Therefore, we further investigated the correlation between LRRRC15 and macrophages infiltration. By using an established immune gene signatures approach,\textsuperscript{45} the GSEA gene set enrichment uncovered the association between LRRRC15 expression and macrophages in rGBM. In the brain, macrophages derived from brain-resident microglia/macrophages and peripheral monocytes/macrophages.\textsuperscript{9,10} The further study employed transcriptional levels of the representative macrophages/microglial markers\textsuperscript{4,41,42} to identify their relationship with LRRRC15 expression. Fortunately, the LRRRC15 expression was positively correlated with the expression of ITGAM, AIF1, CD68, CD206, CD163 and CD204 with M2-like phenotype and was not with NOS2 and STAT1 represented the M1-like functional phenotype.\textsuperscript{43,44} Furthermore, the CGGA database, an independent database, was used as validation (including two data sets). Importantly, our IHC assay also confirmed the LRRRC15 expression promoted the poor prognosis and positively associated with CD206 expression in our rGBM clinical samples. The study also confirmed LRRRC15 could contribute to GAMs infiltration and tumour proliferation in GBM, which was consistent with previous studies that many LRR-containing proteins are involved in tumour progression.\textsuperscript{45-47} Meanwhile, an LRRRC15-targeting antibody-drug conjugate, ABBV-085, is currently being evaluated in a Phase 1 safety study.\textsuperscript{20} Our results indicated LRRRC15 may be an underlying target to harness GAMs biology to affect prognosis for rGBM patients. Furthermore, GAMs could promote immunosuppression through multiple mechanisms in the TME including the up-regulation of PD-L1 and B7-H1.\textsuperscript{48,49} Domínguez et al suggested LRRRC15\textsuperscript{*} carcinoma-associated fibroblasts are associated with poor anti-PD-L1 immunotherapy response.\textsuperscript{50} Thus, the strategies of targeting LRRRC15 to ablate GAMs effects in the rGBM microenvironment could improve effects of immune-checkpoint inhibitors.

Extensive studies also highlighted the heterogeneity of molecular subtypes of GBM in TME to understand the complexity of GBM.\textsuperscript{15,16,51} GBM demonstrated considerable heterogeneity of clinical response for GBM molecular subtypes to current treatments. The molecular subtype heterogeneity is associated with the TME, and the subtypes did not change at recurrence.\textsuperscript{51} Therefore, understanding molecular subtype of rGBM is capable of providing better predictions of rGBM progression and treatment choices. We qualified the tumour purity of different subtypes of rGBM, and the mesenchymal subtype showed the lowest tumour purity, which was consistent with previous studies indicating the expansion of microglia/macrophages in the mesenchymal subtype.\textsuperscript{42,52,53} Our qualified molecular subtypes of rGBM also demonstrated the correlation between mesenchymal subtype with increased levels of M2-like macrophages. The results implied that the mesenchymal subtype could enhance the responsiveness of macrophages-based therapeutic strategies. Interestingly, the expression of LRRRC15 showed a significant increase in the mesenchymal subtype, suggesting targeting LRRRC15 could be more beneficial for rGBM treatments.

In summary, the study comprehensively analysed the rGBM microenvironment gene signatures, and integrated rGBM microenvironment-associated genes and up-DEGs in rGBM to identify a novel prognostic immune-related gene, LRRRC15. Our results confirmed that the high expression of LRRRC15 was associated with the infiltration of GAMs. Meanwhile, we also identified LRRRC15 expression was enriched in mesenchymal subtype with GAMs-rich microenvironment. Our results may aid to interpret the rGBM microenvironment and to provide a novel therapeutic target to improve rGBM prognosis.

ACKNOWLEDGEMENTS

The study was supported by NSFC-Liaoning Joint Fund Key Program (No. U1608281); National Natural Science Foundation of China (No. 81601370); Major Special S&T Projects in Liaoning Province (2019HN1/10300005); Program for Shenyang High Level Talent Innovation and Entrepreneurship Team (2019-SYRCCY-B-01); Shenyang S&T Projects (20-204-4-22).

CONFLICT OF INTEREST

The authors declared that they have no conflicts of interest to this work.

AUTHOR CONTRIBUTIONS

Haichao Tang: Conceptualization (equal); Data curation (lead); Formal analysis (lead); Methodology (equal); Writing-original draft (lead). Wensi Liu: Conceptualization (equal); Formal analysis (equal);
Investigation (equal). Zhaoxu Xu: Data curation (supporting); Formal analysis (equal). Jianhang Zhao: Formal analysis (supporting); Methodology (supporting); Visualization (supporting). Weitao Wang: Data curation (supporting); Validation (supporting). Zhaojin Yu: Conceptualization (equal); Data curation (equal); Formal analysis (equal); Supervision (lead); Writing—original draft (supporting). Minjie Wei: Conceptualization (lead); Funding acquisition (lead); Validation (equal); Writing—original draft (equal).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Minjie Wei https://orcid.org/0000-0002-0404-7098

REFERENCES
1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in. 2010-2014. Neuro Oncol. 2017;19(suppl_5):v1-v88.(1523-5866 (Electronic))
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):979-996.
3. Cloughesy TA-O, Mochizuki AA-OX, Orpilla JA-OX, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(5):477-486.(1546-170X (Electronic))
4. Wang Q, Hu B, Hu X, et al. Tumor Evolution of Glioma—Intrinsic Regions associated with low-grade gliomas using voxel-based lesion symptom mapping. Neuro—oncology. 2015;17(2):282-288.
5. Liu X, Li Y, Qian Z, et al. A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas. Neuroimage Clin. 2018;20:1070-1077.
6. Zhao Z, Meng F, Wang W, Wang Z, Zhang C, Jiang T. Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas. Sci Data. 2017:4:170024.
7. Bao ZS, Chen HM, Yang MY, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 2014;24(11):1765-1773.
8. Yoshihara K, Shamarodgoli M, Fau - Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013:4:2612. (2014-7213 (Electronic))
9. Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16(1):64.
10. Zhang Y, Sime W, Juhas M, Sjolander A. Crossstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. Eur J Cancer. 2013:49(15):3320-3334.
11. Qazilbash MH, Wieder E, Thall PF, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017;31(3):697-704.
12. Ishtsuka K, Utsunomiya A, Ishida T. PD-1 inhibitor therapy in adult t-cell leukemia—lymphoma. N Engl J Med. 2018;379(7):695.
13. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
14. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-421.
15. Iorgulescu JB, Reardon DA, Chiocca EA, Wu CJ. Immuno therapy for glioblastomas: going viral. Nat Med. 2018;24(8):1094-1096.
16. Qull DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31(3):326-341.
17. Jia D, Li S, Li D, Xue H, Yang D, Liu Y. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging. 2018;10(4):592-605.
18. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med. 2005;352(10):997-1003.
19. Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining
the approach based on emerging evidence and current challenges. 

37. Coffelt SB, de Visser KE. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol. 2015;36(4):192-212.

38. Engblom C, Pfirschke C, Pittet M. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16(7):447-462.

39. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immun. 2019;19(6):369-382.

40. Morantz RA, Wood GW, Foster M, Clark M, Gollahon K. Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors. J Neurosurg. 1979;50(3):305-311.

41. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462-472 (1878-3686 Electronic).

42. Galusiewicz K, Rodriguez B, Wei J, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016;1(2):e85841. (2379-3708 Print).

43. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-461.

44. Lisi L, Ciotti GM, Braun D, et al. Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma. Neurosci Lett. 2017;645:106-112.

45. van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol. 1998;102(5):1376-1379.

46. Velloso FJ, Trombetta-Lima M, Anschau V, Sogayar MC, Correa RG. NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer. Biosci Rep. 2019;39(4):BRS20181709.

47. Kajander T, Kuja-Panula J, Rauvala H, Goldman A. Crystal structure and role of glycans and dimerization in folding of neuronal leucine-rich repeat protein AMIGO-1. J Mol Biol. 2011;413(5):1001-1015.

48. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19(12):3165-3175.

49. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci. 2003;100(9):5336.

50. Dominguez CX, Muller S, Keerthivasan S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 2019.

51. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRα, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.

52. Doucette T, Rao G, Rao A, et al. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immun Res. 2013;1:112-122.

53. Wei J, Marisetty A, Schrand B, et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J clin invest. 2019;129(1):137-149.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Tang H, Liu W, Xu Z, et al. Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration. J Cell Mol Med. 2021;25:5534–5546. https://doi.org/10.1111/jcmm.16563